Veranex Presents Study Results at the National Kidney Foundation Spring Clinical Meeting
Dr. Manasi Datar and colleagues used conjoint analysis to estimate preferences regarding kidney disease testing from 401 PCPs via a web survey....
Study by Veranex and Proteomics International Demonstrates Clinical Utility of Prognostic Test for Type 2 Diabetes Patients
admin.veranex : Mar 24, 2025 10:23:07 PM
By conducting a clinical utility study for Proteomics International’s PromarkerD (a blood-based test that predicts the risk of kidney disease/decline in Type 2 diabetes patients), Veranex provided evidence of the test’s value to physicians and its ability to affect patient management.
1 min read
Medicare Clarifies Confusion Over Tests Covered by the NGS NCD
Gary Keeler : Mar 24, 2025 10:23:13 PM
The Medicare NGS NCD grants national coverage for somatic testing in patients with advanced cancer if the test has FDA-approval or -clearance as a...
DTx Part I: Identifying Optimal Payment Models for Digital Therapeutics
Gary Keeler : Mar 24, 2025 10:23:12 PM
According to the Digital Therapeutics Alliance (DTA), digital therapeutics (DTx) are products that deliver “software-generated therapeutic...